Clinical Research Directory
Browse clinical research sites, groups, and studies.
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
Sponsor: AdventHealth
Summary
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Official title: RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-09-20
Completion Date
2027-10-10
Last Updated
2024-10-24
Healthy Volunteers
No
Conditions
Interventions
18F-rhPSMA-7.3 (Posluma)
PET Scan using Posluma for detection of early recurrence of prostate cancer.
Locations (1)
AdventHealth
Orlando, Florida, United States